🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

Inspire Medical stock surges on CEO comments

Published 09/04/2024, 12:14 PM
© Reuters.
INSP
-

Shares of Inspire Medical Systems (NYSE:INSP) Inc. experienced a significant surge, climbing up to 12% following the company's announcement that it anticipates weight-loss medications to expand the number of eligible candidates for its sleep apnea treatment device.

The medical-device maker's CEO, Timothy P. Herbert, addressed the Morgan Stanley Healthcare Conference, highlighting the issue that many patients are currently ineligible for Inspire therapy due to their high Body Mass Index (BMI).

Herbert explained that the company is actively engaging with physicians to increase awareness about the benefits of GLP-1 medications. These drugs are intended to aid in weight loss, which can subsequently decrease the severity of obstructive sleep apnea, making more patients suitable for the company's implant.

He emphasized that while GLP-1 drugs are not directly aimed at treating obstructive sleep apnea, they can play a supportive role in managing the condition by helping patients reduce their BMI.

The CEO's remarks at the conference underscore the potential for these weight-loss drugs to indirectly benefit Inspire Medical by increasing the pool of patients who can qualify for their sleep apnea implant. This development is particularly relevant for those who have been previously unable to receive the therapy due to weight restrictions associated with a high BMI.

Inspire Medical's focus on collaboration with healthcare professionals to educate them about the GLP-1 drugs' weight loss benefits reflects the company's strategy to widen its market reach. This approach aims to facilitate access to its sleep apnea treatment for a larger segment of patients who suffer from this condition.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.